Financial Enhancement Group LLC bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 41,818 shares of the company's stock, valued at approximately $1,882,000. Financial Enhancement Group LLC owned about 0.07% of Protagonist Therapeutics at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Protagonist Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company's stock valued at $95,000 after acquiring an additional 379 shares during the period. GAMMA Investing LLC raised its holdings in shares of Protagonist Therapeutics by 749.2% during the third quarter. GAMMA Investing LLC now owns 552 shares of the company's stock valued at $25,000 after acquiring an additional 487 shares during the period. Exchange Traded Concepts LLC acquired a new stake in shares of Protagonist Therapeutics during the third quarter valued at approximately $43,000. CWM LLC raised its holdings in shares of Protagonist Therapeutics by 910.3% during the third quarter. CWM LLC now owns 1,273 shares of the company's stock valued at $57,000 after acquiring an additional 1,147 shares during the period. Finally, ProShare Advisors LLC raised its holdings in shares of Protagonist Therapeutics by 9.2% during the first quarter. ProShare Advisors LLC now owns 14,345 shares of the company's stock valued at $415,000 after acquiring an additional 1,206 shares during the period. 98.63% of the stock is owned by institutional investors and hedge funds.
Protagonist Therapeutics Stock Up 0.0 %
Shares of PTGX traded up $0.01 during mid-day trading on Thursday, hitting $47.61. 427,853 shares of the company's stock were exchanged, compared to its average volume of 735,720. The firm has a fifty day moving average of $45.47 and a two-hundred day moving average of $37.88. Protagonist Therapeutics, Inc. has a twelve month low of $14.78 and a twelve month high of $48.89. The stock has a market cap of $2.80 billion, a price-to-earnings ratio of 18.17 and a beta of 2.17.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.50) EPS for the quarter, hitting the consensus estimate of ($0.50). The business had revenue of $4.17 million for the quarter, compared to analyst estimates of $40.00 million. On average, equities analysts predict that Protagonist Therapeutics, Inc. will post 2.46 earnings per share for the current year.
Insider Buying and Selling
In related news, CFO Asif Ali sold 14,203 shares of the company's stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $44.49, for a total transaction of $631,891.47. Following the completion of the sale, the chief financial officer now directly owns 34,960 shares of the company's stock, valued at approximately $1,555,370.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director William D. Waddill sold 8,000 shares of the company's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total transaction of $360,000.00. Following the completion of the sale, the director now directly owns 12,000 shares of the company's stock, valued at approximately $540,000. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Asif Ali sold 14,203 shares of the stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $44.49, for a total transaction of $631,891.47. Following the completion of the sale, the chief financial officer now directly owns 34,960 shares of the company's stock, valued at approximately $1,555,370.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.40% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the stock. StockNews.com upgraded shares of Protagonist Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, August 8th. HC Wainwright upped their price objective on shares of Protagonist Therapeutics from $40.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, September 12th. JPMorgan Chase & Co. upped their price objective on shares of Protagonist Therapeutics from $39.00 to $48.00 and gave the company an "overweight" rating in a research note on Thursday, July 25th. Truist Financial assumed coverage on shares of Protagonist Therapeutics in a research note on Monday, September 9th. They issued a "buy" rating and a $60.00 price objective on the stock. Finally, TD Cowen upgraded shares of Protagonist Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 25th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $53.57.
Get Our Latest Stock Analysis on PTGX
Protagonist Therapeutics Company Profile
(
Free Report)
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
See Also
Before you consider Protagonist Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.
While Protagonist Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
